{"id":389307,"date":"2022-12-28T00:00:00","date_gmt":"2022-12-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0006-2022-biopharma-asthma-china-in-depth-china-2022\/"},"modified":"2026-03-31T10:35:27","modified_gmt":"2026-03-31T10:35:27","slug":"concim0006-2022-biopharma-asthma-china-in-depth-china-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0006-2022-biopharma-asthma-china-in-depth-china-2022\/","title":{"rendered":"Asthma | China In-Depth | China | 2022"},"content":{"rendered":"<p>Asthma is a common chronic airway disease that affects children and adults. Environmental factors and a rapidly changing lifestyle have increased the incidence and prevalence of asthma in China. The asthma therapy market in China consists of many well-established agents, including inhaled agents (GSK\u2019s Advair \/ Seretide, AstraZeneca\u2019s Symbicort), oral drugs (montelukast), and biologics (Roche \/ Novartis\u2019s Xolair). However, the market is evolving as generic alternatives to inhaled blockbuster agents continue to launch. Novel targeted therapies\u2014benralizumab (AstraZeneca\u2019s Fasenra) and mepolizumab (GSK\u2019s Nucala)\u2014are also in late-phase development in China for asthma. The launch and uptake of these agents will lead to significant growth of China\u2019s asthma therapy market over 2021-2031. In addition, ongoing reforms in China\u2019s regulatory and access and reimbursement landscape will increasingly encourage multinational companies to enter the market.<\/p>\n<ul>\n<li>How large is China\u2019s drug-treatable asthma population, and how will drug-treatment rates change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s asthma market and why? What are interviewed experts\u2019 insights into current treatment options?<\/li>\n<li>What are the market access considerations for key therapies in the asthma pipeline in China? What sales could they secure in asthma? What are interviewed experts\u2019 opinions of these therapies?<\/li>\n<li>What are the key drivers of and constraints in China\u2019s asthma therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>China In-Depth:<\/em> Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Release date<\/strong><\/p>\n<p>December 2022<\/p>\n<p><strong>Geography<\/strong><\/p>\n<p>China<\/p>\n<p><strong>Primary research <\/strong><\/p>\n<p>Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 25 pulmonologists and 25 PCPs.<\/p>\n<p><strong>Epidemiology<\/strong><\/p>\n<p>Diagnosed prevalence of asthma in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales, and patient share of key asthma therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p><strong>EMERGING THERAPIES <\/strong><\/p>\n<p>Phase III\/PR: 6 drugs; Phase II: 3 drugs; coverage of Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-389307","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389307\/revisions"}],"predecessor-version":[{"id":392438,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389307\/revisions\/392438"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}